Unichem Laboratories is currently trading at Rs. 248.75, up by 11.90 points or 5.02% from its previous closing of Rs. 236.85 on the BSE.
The scrip opened at Rs. 238.75 and has touched a high and low of Rs. 258.05 and Rs. 237.45 respectively. So far 59505 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 382.00 on 08-Jan-2018 and a 52 week low of Rs. 231.40 on 05-Jun-2018.
Last one week high and low of the scrip stood at Rs. 258.05 and Rs. 232.60 respectively. The current market cap of the company is Rs. 1681.05 crore.
The promoters holding in the company stood at 50.67%, while Institutions and Non-Institutions held 11.27% and 38.06% respectively.
Unichem Laboratories has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the United States District Court for the District of New Jersey regarding Unichem's Abbreviated New Drug Application (ANDA) for generic tadalafil (Cialis).
As per the agreement, the company expects to launch its generic tadalafil product in the United States on or not before March 26, 2019 under certain circumstances.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: